← VERTEX PHARMACEUTICALS INC / MA
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Net Income (Loss) Attributable to Parent | ($112.1m) |
$263.5m
+335.14%
|
$2.1b
+695.83%
|
$1.2b
-43.88%
|
$2.7b
+130.42%
|
$2.3b
-13.63%
|
$3.3b
+41.84%
|
$3.6b
+8.96%
|
($535.6m)
-114.80%
|
$4.0b
+838.09%
|
— | |
| Net Income (Loss) Available to Common Stockholders, Basic | — | $263.2m |
$2.1b
+696.53%
|
$1.2b
-43.87%
|
$2.7b
+130.42%
|
— | — | — | — | — | — | |
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ($84.0m) | $91.6m | $2.1b | $1.2b | $2.7b | — | — | — | — | — | — | |
| Net Income (Loss) Attributable to Noncontrolling Interest | — | ($171.8m) | ($9.8m) | $0 | $0 | — | — | — | — | — | — | |
| Depreciation, Depletion and Amortization | $61.4m | $61.4m | $72.4m | $106.9m | $109.5m | $125.6m | $148.3m | $181.3m | $207.2m | $209.8m | $222.1m | |
| Depreciation | $60.8m | $61.4m | $72.4m | $106.9m | $109.5m | $125.6m | $148.3m | $167.8m | $160.4m | $155.8m | $222.1m | |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | $1.7m | $20.2m | $20.2m | — | |
| Capitalized Computer Software, Amortization | — | — | — | — | — | — | — | $11.8m | $25.2m | $31.2m | — | |
| Deferred Income Tax Expense (Benefit) | $16.9m | ($127.5m) | ($1.5b) | $167.4m | $277.3m | ($154.6m) | ($275.9m) | ($536.5m) | ($348.8m) | ($510.8m) | ($340.4m) | |
| Share-based Payment Arrangement, Noncash Expense | $237.7m | $290.7m | $325.0m | $360.5m | $429.5m | $441.4m | $491.3m | $581.2m | $698.5m | $685.9m | $689.1m | |
| Payment, Tax Withholding, Share-based Payment Arrangement | — | — | — | — | $200.3m | $135.9m | $172.0m | $226.1m | $405.0m | $369.9m | — | |
| Share-based Payment Arrangement, Expense | $237.7m | $290.7m | $325.0m | $360.5m | $429.5m | $441.4m | $491.3m | $581.2m | $698.5m | $685.9m | $689.1m | |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) | — | $255.3m | $29.0m | $0 | $0 | — | — | — | — | $379.0m | — | |
| Other Nonoperating Income (Expense) | $4.1m | ($81.4m) | ($790k) | $192.2m | $296.4m | $4.9m | ($164.8m) | ($22.8m) | ($86.1m) | ($7.7m) | — | |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts Receivable | $33.0m | $71.8m | $108.2m | $225.6m | $223.4m | $274.7m | $358.6m | $84.1m | $99.3m | $347.3m | ($259.7m) | |
| Increase (Decrease) in Inventories | $16.4m | $45.0m | $32.0m | $64.0m | $132.0m | $92.8m | $136.4m | $322.9m | $517.3m | $524.2m | ($333.9m) | |
| Inventory Write-down | — | $15.3m | $20.4m | — | — | — | — | — | — | — | — | |
| Increase (Decrease) in Accounts Payable | ($11.7m) | $8.8m | $36.6m | ($22.8m) | $51.3m | $31.9m | $120.8m | $48.7m | $49.5m | $36.8m | ($28.1m) | |
| Net Cash Provided by (Used in) Operating Activities | $236.1m |
$844.9m
+257.87%
|
$1.3b
+50.34%
|
$1.6b
+23.54%
|
$3.3b
+107.32%
|
$2.6b
-18.75%
|
$4.1b
+56.23%
|
$3.5b
-14.35%
|
($492.6m)
-113.93%
|
$3.6b
+837.19%
|
$4.3b
+18.22%
|
|
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Property, Plant, and Equipment | $56.6m | $99.4m | $95.5m | $75.5m | $259.8m | $235.0m | $204.7m | $200.4m | $297.7m | $437.6m | ($496.8m) | |
| Debt Securities, Available-for-sale, Realized Gain (Loss) | ($616.6m) | ($532.6m) | ($431.9m) | ($537.2m) | ($431.4m) | ($528.2m) | $0 | $0 | $0 | $0 | — | |
| Gain (Loss) on Sale of Investments | — | ($76.6m) | ($1.1m) | $0 | — | — | — | — | — | — | — | |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale | $757.6m | $369.2m | $431.6m | $475.9m | $372.3m | $499.3m | $920.0m | $839.1m | $4.5b | $5.9b | — | |
| Unrealized Gain (Loss) on Investments | — | — | $2.6m | $132.5m | $136.2m | $17.1m | ($149.1m) | ($7.5m) | ($9.5m) | ($11.3m) | — | |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | $1.2b | $0 | $0 | $295.9m | $0 | $0 | — | $258.0m | |
| Payments for (Proceeds from) Other Investing Activities | $7k | ($436k) | ($75k) | $0 | — | — | — | — | $54.0m | $24.7m | — | |
| Net Cash Provided by (Used in) Investing Activities | $104.5m | ($437.7m) | ($202.2m) | ($1.2b) | $99.4m | ($340.9m) | ($321.1m) | ($3.1b) | ($3.8b) | ($945.4m) | ($882.8m) | |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common Stock | — | — | $350.0m | $192.0m | $539.1m | $1.4b | $0 | $427.6m | $1.2b | $2.0b | — | |
| Proceeds from (Payments for) Other Financing Activities | — | — | ($394k) | ($2.0m) | ($1.8m) | $5.7m | $3.5m | — | $6.2m | $3.7m | — | |
| Net Cash Provided by (Used in) Financing Activities | $133.3m |
$68.4m
-48.67%
|
($71.2m)
-204.12%
|
$126.8m
+278.00%
|
($505.3m)
-498.57%
|
($1.5b)
-192.51%
|
($67.7m)
+95.42%
|
($562.2m)
-730.43%
|
($1.5b)
-165.90%
|
($2.3b)
-51.27%
|
($2.2b)
+2.83%
|
|
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | $415.9m | $435.8m | $990.7m | $462.4m | $2.9b | $811.2m | $3.7b | ($139.7m) | ($5.8b) | $515.6m | $6.2b | |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $415.9m | $435.8m | $2.7b | $3.1b | $6.0b | $6.8b | $10.5b | $10.4b | $4.6b | $5.1b | $6.2b | |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ($4.7m) | $5.8m | ($6.2m) | $1.6m | $20.6m | ($13.4m) | ($29.2m) | $26.9m | ($42.6m) | $90.9m | ($40.8m) | |
| Additional Supplementary Disclosures | ||||||||||||
| Additional Supplementary Disclosures | ||||||||||||
| Proceeds from Stock Options Exercised | — | $323.3m | $263.4m | $317.8m | $228.2m | $64.2m | $144.6m | $80.8m | $50.0m | $55.6m | — | |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating Activities | $83.7m | $68.7m | $66.5m | $55.6m | $54.5m | $56.3m | $52.3m | $43.1m | $30.5m | $12.4m | — | |
| Income Taxes Paid, Net | ($2.6m) | $6.4m | $12.4m | $24.7m | $191.8m | $476.3m | $1.1b | $1.7b | $1.1b | $1.6b | — | |
| Additional Financial Items | ||||||||||||
| Equity Securities, FV-NI, Unrealized Gain (Loss) | — | — | — | $197.6m | $311.9m | $17.1m | ($149.1m) | ($600k) | ($57.7m) | — | — | |
| Foreign Currency Transaction Gain (Loss), before Tax | $4.0m | $5.5m | ($1.1m) | ($5.2m) | ($16.1m) | ($13.9m) | ($15.1m) | ($24.6m) | ($27.3m) | ($13.7m) | — | |
| Goodwill | $50.4m | $50.4m | $50.4m | $1.0b | $1.0b | $1.0b | $1.1b | $1.1b | $1.1b | $1.1b | $0 | |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | ($112.1m) | — | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | ($84.0m) | — | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | $0 | — | — | — | — | — | — | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | $0 | — | — | — | — | — | — | — | — | — | — | |
| Income Tax Expense (Benefit) | $16.7m | ($107.3m) | ($1.5b) | $218.1m | $405.2m | $388.3m | $910.4m | $760.2m | $784.1m | $690.0m | — | |
| Interest Expense Nonoperating | — | — | — | — | — | — | — | — | $30.6m | $13.3m | — |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.